Skip to main content

Table 1 Adverse events related to the cardiovascular system in studies of CA4P

From: Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management

Study

 

Phase II single-arm CA4P (63 mg/m2) + CP

(n = 44)

[17]

Phase II, two-arma Bev (15 mg/kg) + CA4P (60 mg/m2) (n = 54) OR Bev (n = 53)

[18, 24]

Phase II single-arm CA4P (60 mg/m2) + CP

(n = 51)

[15]

Phase II, two-arma CP + Bev (15 mg/kg) + CA4P (60 mg/m2) (n = 31) OR CP + Bev (n = 29)

[16]

Phase I single-arm CA4P (doses from 18 mg/m2 to 90 mg/m2)

(n = 25)

[21, 22]b

Phase I single-arm CA4P (doses from 5 mg/m2 to 114 mg/m2)

(n = 34)

[20]

Phase I single-arm CA4P (doses from 45 mg/m2 to 63 mg/m2) + Bev (10 mg/kg)

(n = 15)

[23]

Tumor type

 

Platinum-resistant ovarian cancer

Recurrent ovarian cancer

Anaplastic thyroid cancer

Stage IIIb/IV NSCLC

Solid tumors

Solid tumors

Solid tumors

Hypertension, n (%)

All-grades

10 (23)

32/53 (60)

17 (33)

17 (55)

1 (4)

12 (35)

11 (73)

 

Grade ≤ 2

10 (23)

NR

15 (29)

NR

1 (4)

12 (35)

11 (73)

 

Grade 3

0

19 (35)

2 (4)

NR

0

0

0

 

Grade 4

0

NR

0

0

Tachycardia, n (%)

All-grades

15 (34)

2 (4)

6 (12)

8 (26)

NR

19 (56)

1 (7)

 

Grade ≤ 2

14 (32)

NR

6 (12)

NR

NR

19 (56)

1 (7)

 

Grade 3

1 (2)

NR

0

NR

NR

0

0

 

Grade 4

NR

0

NR

NR

0

Bradycardia, n (%)

All-grades

1 (2)

3 (6)

2 (4)

4 (13)

NR

8 (24)

NR

 

Grade ≤ 2

1 (2)

NR

1 (2)

NR

NR

8 (24)

NR

 

Grade 3

0

NR

1 (2)

NR

NR

0

NR

 

Grade 4

NR

0

NR

NR

NR

Hypotension, n (%)

All grades

2 (5)

3 (6)

NR

NR

NR

6 (18)

NR

 

Grade ≤ 2

2 (5)

NR

NR

NR

NR

6 (18)

NR

 

Grade 3

0

NR

NR

NR

NR

1 (3)

NR

 

Grade 4

NR

NR

NR

NR

NR

Arrhythmia, n (%)

All grades

2 (5)

2 (4)

0

NR

2 (8)

NR

1 (7)

 

Grade ≤ 2

1 (2)

NR

0

NR

2 (8)

NR

0

 

Grade 3

1 (2)

NR

0

NR

0

NR

1 (7)

 

Grade 4

NR

0

NR

0

NR

0

Myocardial ischemia, n (%)

All grades

1 (2)

NR

2 (4)

2 (6)

2 (8)c

NR

NR

 

Grade ≤ 2

1 (2)

NR

2 (4)

0

1 (4)

NR

NR

 

Grade 3

0

NR

0

2 (6)

0

NR

NR

 

Grade 4

NR

0

0

1 (4)c

NR

NR

>QTc, n (%)

All grades

2 (5)

NR

8 (16)

NR

7 (28)

0

NR

 

Grade ≤ 2

2 (5)

NR

6 (12)

NR

7 (28)

0

NR

 

Grade 3

0

NR

2 (4)

NR

0

0

NR

 

Grade 4

NR

0

NR

0

0

NR

AV block, n (%)

All grades

NR

NR

1 (2)

NR

NR

NR

NR

 

Grade ≤ 2

NR

NR

1 (2)

NR

NR

NR

NR

 

Grade 3

NR

NR

0

NR

NR

NR

NR

 

Grade 4

NR

NR

0

NR

NR

NR

NR

  1. aIn two-arm studies, adverse events are shown only for the CA4P-containing arms
  2. bThese manuscripts describe the same patient cohort so safety data were combined
  3. cGrade 4 myocardial ischemia occurred in a patient receiving 90 mg/m2 of CA4P
  4. AV atrioventricular, Bev bevacizumab, CA4P combretastatin A4-phosphate, CP carboplatin and paclitaxel, MI myocardial infarction, NR not reported, NSCLC non–small cell lung cancer
Back to article page

Gynecologic Oncology Research and Practice

ISSN: 2053-6844

Contact us